Company profile for AOBiome Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes ...
AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing microbiome-based therapies for local, nasal and systemic inflammatory conditions. Founded in 2012 by PatientsLikeMe founder Jamie Heywood and MIT-trained Chemical Engineer David Whitlock, AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes multiple clinical-stage programs: a completed Phase 2 study to treat patients with acne vulgaris or acne, a Phase 1b study to treat patients with pediatric eczema (atopic dermatitis).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
125 Cambridge Park Dr 5th Floor Cambridge, Massachusetts 02140
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251007459013/en/Veristat-and-AOBiome-Therapeutics-to-Present-at-Clinical-Outsourcing-Group-on-Essential-Elements-of-Effective-Partnerships-with-CROs

BUSINESSWIRE
07 Oct 2025

https://www.prnewswire.com/news-releases/aobiome-announces-the-publication-of-positive-phase-2b-results-in-the-lancets-eclinicalmedicine-for-b244-in-the-treatment-of-mild-to-moderate-atopic-dermatitis-and-moderate-to-severe-pruritus-301826082.html

PR NEWSWIRE
16 May 2023

https://www.prnewswire.com/news-releases/aobiome-therapeutics-granted-composition-of-matter-patent-for-its-clinical-candidate-b244-301791237.html

PR NEWSWIRE
06 Apr 2023

https://www.clinicaltrialsarena.com/news/aobiome-b244-pruritus-eczema/

CLINICALTRIALSARENA
22 Feb 2022

https://www.prnewswire.com/news-releases/aobiome-achieves-landmark-recruitment-goal-in-largest-clinical-trial-ever-powered-by-a-live-topical-biotherapeutic-301424800.html

PRNEWSWIRE
16 Nov 2021

https://www.prnewswire.com/news-releases/new-30-patient-study-of-aobiomes-new-shelf-stable-formulation-of-its-ammonia-oxidizing-bacteria-aob-shows-reduction-of-itch-levels-in-both-pediatric-and-adult-subjects-who-suffer-from-eczema-301356425.html

PRNEWSWIRE
17 Aug 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty